Imugene (ASX:IMU) is preparing to initiate this year the clinical program for its Her-Vaxx peptide vaccine, a B-cell based immunotherapy for HER-2 positive gastric & breast cancer.
Her-Vaxx has potential to improve upon Roche’s blockbuster Herceptin drug that generated annualised sales of $6.9 billion and targets the same biomarker.
It was developed by one of Europe’s leading cancer institutes with about $10 million already invested in the technology.
Charles Walker, managing director. outlined these points and many others at the February 2015 Proactive Investors Melbourne / Sydney Luncheons.
The full presentation can be ACCESSED HERE.
- Forums
- ASX - By Stock
- IMU
- News: Imugene progressing cancer vaccine towards clinical studies
News: Imugene progressing cancer vaccine towards clinical studies
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $768.4M |
Open | High | Low | Value | Volume |
10.5¢ | 10.8¢ | 10.0¢ | $746.7K | 7.120M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
176 | 10004604 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 420568 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
176 | 10004604 | 0.100 |
12 | 525784 | 0.099 |
10 | 716843 | 0.098 |
11 | 640958 | 0.097 |
10 | 772491 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 420568 | 8 |
0.110 | 7967553 | 66 |
0.115 | 6445983 | 53 |
0.120 | 11666760 | 87 |
0.125 | 13968032 | 53 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
10.3¢ |
  |
Change
0.000 ( 2.40 %) |
|||
Open | High | Low | Volume | ||
10.3¢ | 10.5¢ | 10.3¢ | 1930285 | ||
Last updated 15.59pm 28/03/2024 ? |
Featured News
IMU (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online